Clinical lab tests
This article was originally published in The Gray Sheet
Executive Summary
Final rule establishing national Medicare coverage policies for 23 clinical diagnostic laboratory tests, including prothrombin time and fecal occult blood tests, is published Nov. 23 in the Federal Register. The rule incorporates six changes to a March 2000 proposed rule, including removing "egregious overutilization" as an exception Medicare contractors may use to pursue frequency-based denial of claims, and removing a provision in the "reasons for denial" section limiting coverage of non-FDA-approved devices to category B IDEs. CMS notes that it will be modifying regulations on IDEs following the creation of a clinical trials coverage policy in September 2000. In addition, the effective date for provisions requiring computer system adjustments is changed to Nov. 25, 2002. All other provisions are effective Feb. 21, 2002...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.